Research & Innovation

Spin-offs

The Knowledge-Based Companies (commonly known as “spin-offs”) of IR Sant Pau arise from the centre’s scientific and innovation activities to transform knowledge into impactful solutions. These initiatives reinforce IR Sant Pau’s strategic mission by bringing research and innovation closer to clinical practice.

Active Technology-Based Companies: 4

Fundation: 2025

Base4 is an innovative spin-off from the Sant Pau Hospital Research Institute focused on developing advanced solutions for personalized health.

Its mission is to transform the medical model towards a preventive and precision approach, using technology capable of predicting the biological age of different body tissues. Based on this information, the company develops personalized interventions aimed at reversing the aging process and improving the overall health of patients.

Visit website

Fundation: 2021

Ephion Health is a startup supported by the Sant Pau Research Institute that develops digital solutions based on artificial intelligence for patient monitoring.

Its mission is to improve clinical follow-up and facilitate medical decision-making through the use of digital biomarkers. Using data collected by wearable devices, its technology allows for an objective and continuous assessment of mobility and health status, contributing to more personalized and efficient medicine.

Visit website

Fundation: 2021

Ivestatin was born from the research results of IR Sant Pau as a biotechnology company focused on the development of new therapies for the treatment of ischemic damage associated with cardiovascular diseases.

Its mission is to improve the quality of life of patients through innovative solutions that reduce the damage caused by events such as heart attacks or strokes. The company works on developing treatments that protect tissues and increase patient survival and recovery.

Visit website

Fundation: 2017

Nanoligent is a spin-off from the Sant Pau Research Institute and the Autonomous University of Barcelona (UAB) focused on the development of targeted nanopharmaceuticals, primarily in the field of oncology.

Its mission is to develop precision medicines capable of acting selectively on tumor cells, improving treatment efficacy and reducing adverse effects. Through the use of nanobiotechnology and protein engineering, the company creates innovative drug delivery systems that allow for greater therapeutic specificity.

Visit website